Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells

Vaccine

Volumn 26, Issue 20, 2008, Pages 2537-2544

  Carrión, Javier ^a   Folgueira, Cristina ^a   Alonso, Carlos ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Dendritic cell; DNA vaccine; Histones; Leishmania; Treg cell; Visceral leishmaniosis

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; DNA VACCINE; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNIZATION; LEISHMANIA INFANTUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; VISCERAL LEISHMANIASIS;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DENDRITIC CELLS; FEMALE; HISTONES; IMMUNOGLOBULIN G; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; SPLEEN; T-LYMPHOCYTES, REGULATORY; VACCINES, DNA;

EID: 42649113387     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.003     Document Type: Article

References (66)

1. Murray H.W., Berman J.D., Davies C.R., and Saravia N.G. Advances in leishmaniasis. Lancet 366 9496 (2005) 1561-1577
2. Croft S.L., Vivas L., and Brooker S. Recent advances in research and control of malaria, leishmaniasis, trypanosomiasis and schistosomiasis. East Mediterr Health J 9 4 (2003) 518-533
3. Choi C.M., and Lerner E.A. Leishmaniasis as an emerging infection. J Investig Dermatol Symp Proc 6 3 (2001) 175-182
4. Requena J.M., Iborra S., Carrion J., Alonso C., and Soto M. Recent advances in vaccines for leishmaniasis. Expert Opin Biol Ther 4 9 (2004) 1505-1517
5. Santarem N., Silvestre R., Tavares J., Silva M., Cabral S., Maciel J., et al. Immune response regulation by Leishmania secreted and nonsecreted antigens. J Biomed Biotechnol 2007 6 (2007) 85154
6. Chang K.P., and McGwire B.S. Molecular determinants and regulation of Leishmania virulence. Kinetoplastid Biol Dis 1 1 (2002) 1
7. Chang K.P., Reed S.G., McGwire B.S., and Soong L. Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop 85 3 (2003) 375-390
8. Wilson M.E., Jeronimo S.M., and Pearson R.D. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 38 4 (2005) 147-160
9. Pearson R.D., and Sousa A.Q. Clinical spectrum of Leishmaniasis. Clin Infect Dis 22 1 (1996) 1-13
10. Vanloubbeeck Y., and Jones D.E. The immunology of Leishmania infection and the implications for vaccine development. Ann N Y Acad Sci 1026 (2004) 267-272
11. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., de Souza E.P., Luz K.G., Palatnik M., et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN). Vaccine 19 9-10 (2000) 1082-1092
12. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 20 27-28 (2002) 3277-3284
13. Santos F.N., Borja-Cabrera G.P., Miyashiro L.M., Grechi J., Reis A.B., Moreira M.A., et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine. Vaccine 25 33 (2007) 6176-6190
14. de Andrade R.A., Reis A.B., Gontijo C.M., Braga L.B., Rocha R.D., Araujo M.S., et al. Clinical value of anti-Leishmania (Leishmania) chagasi IgG titers detected by flow cytometry to distinguish infected from vaccinated dogs. Vet Immunol Immunopathol 116 1-2 (2007) 85-97
15. Parra L.E., Borja-Cabrera G.P., Santos F.N., Souza L.O., Palatnik-de-Sousa C.B., and Menz I. Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Vaccine 25 12 (2007) 2180-2186
16. Dantas-Torres F. Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Vet Parasitol 141 1-2 (2006) 1-8
17. Saraiva E.M., de Figueiredo Barbosa A., Santos F.N., Borja-Cabrera G.P., Nico D., Souza L.O., et al. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 24 13 (2006) 2423-2431
18. Nogueira F.S., Moreira M.A., Borja-Cabrera G.P., Santos F.N., Menz I., Parra L.E., et al. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 23 40 (2005) 4805-4810
19. Silvestre R., Cordeiro-Da-Silva A., Santarem N., Vergnes B., Sereno D., and Ouaissi A. SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection. J Immunol 179 5 (2007) 3161-3170
20. Carrion J., Nieto A., Iborra S., Iniesta V., Soto M., Folgueira C., et al. Immunohistological features of visceral leishmaniasis in BALB/c mice. Parasite Immunol 28 5 (2006) 173-183
21. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18 (2000) 927-974
22. Melby P.C., Ogden G.B., Flores H.A., Zhao W., Geldmacher C., Biediger N.M., et al. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect Immun 68 10 (2000) 5595-5602
23. Dondji B., Perez-Jimenez E., Goldsmith-Pestana K., Esteban M., and McMahon-Pratt D. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun 73 8 (2005) 5286-5289
24. Aguilar-Be I., da Silva Zardo R., Paraguai de Souza E., Borja-Cabrera G.P., Rosado-Vallado M., Mut-Martin M., et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 73 2 (2005) 812-819
25. Rafati S., Zahedifard F., and Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24 12 (2006) 2169-2175
26. Sukumaran B., Tewary P., Saxena S., and Madhubala R. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 21 11-12 (2003) 1292-1299
27. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., and Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174 11 (2005) 7160-7171
28. Fragaki K., Suffia I., Ferrua B., Rousseau D., Le Fichoux Y., and Kubar J. Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters. Vaccine 19 13-14 (2001) 1701-1709
29. Ramiro M.J., Zarate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21 19-20 (2003) 2474-2484
30. Saldarriaga O.A., Travi B.L., Park W., Perez L.E., and Melby P.C. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. Vaccine 24 11 (2006) 1928-1940
31. Dumonteil E. DNA Vaccines against protozoan parasites: Advances and Challenges. J Biomed Biotechnol 2007 6 (2007) 90520
32. Moll H. Dendritic cells as a tool to combat infectious diseases. Immunol Lett 85 2 (2003) 153-157
33. Steinman R.M. Dendritic cells: understanding immunogenicity. Eur J Immunol 37 Suppl. 1 (2007) S53-S60
34. Flohe S.B., Bauer C., Flohe S., and Moll H. Antigen-pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major. Eur J Immunol 28 11 (1998) 3800-3811
35. Ahuja S.S., Reddick R.L., Sato N., Montalbo E., Kostecki V., Zhao W., et al. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol 163 7 (1999) 3890-3897
36. Ponce L.V., Corado J., Diaz N.L., and Tapia F.J. Adoptive transfer of dendritic cells modulates immunogenesis and tolerogenesis in a neonatal model of murine cutaneous leishmaniasis. Kinetoplastid Biol Dis 4 1 (2005) 2
37. Soto M., Requena J.M., Quijada L., Garcia M., Guzman F., Patarroyo M.E., et al. Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis. Immunol Lett 48 3 (1995) 209-214
38. Soto M., Requena J.M., Quijada L., Gomez L.C., Guzman F., Patarroyo M.E., et al. Characterization of the antigenic determinants of the Leishmania infantum histone H3 recognized by antibodies elicited during canine visceral leishmaniasis. Clin Exp Immunol 106 3 (1996) 454-461
39. Soto M., Requena J.M., Quijada L., Perez M.J., Nieto C.G., Guzman F., et al. Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis. Clin Exp Immunol 115 2 (1999) 342-349
40. Iborra S., Soto M., Carrion J., Alonso C., and Requena J.M. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Vaccine 22 29-30 (2004) 3865-3876
41. Carrion J., Folgueira C., and Alonso C. Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines. Vaccine (2008)
42. Carrion J., Nieto A., Soto M., and Alonso C. Adoptive transfer of dendritic cells pulsed with Leishmania infantum nucleosomal histones confers protection against cutaneous leishmaniosis in BALB/c mice. Microbes Infect 9 6 (2007) 735-743
43. Scott P., Pearce E., Natovitz P., and Sher A. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol 139 1 (1987) 221-227
44. Buffet P.A., Sulahian A., Garin Y.J., Nassar N., and Derouin F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother 39 9 (1995) 2167-2168
45. Alexander J., and Bryson K. T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett 99 1 (2005) 17-23
46. McMahon-Pratt D., and Alexander J. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?. Immunol Rev 201 (2004) 206-224
47. Louis J., Himmelrich H., Parra-Lopez C., Tacchini-Cottier F., and Launois P. Regulation of protective immunity against Leishmania major in mice. Curr Opin Immunol 10 4 (1998) 459-464
48. Ouaissi A. Functional genomics and immunological approaches toward a comprehensive view of protozoan parasite virulence factors. Exp Rev Anti-infect Ther 5 4 (2007) 535-538
49. Bogdan C., Gessner A., Solbach W., and Rollinghoff M. Invasion, control and persistence of Leishmania parasites. Curr Opin Immunol 8 4 (1996) 517-525
50. Stober C.B., Lange U.G., Roberts M.T., Alcami A., and Blackwell J.M. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol 175 4 (2005) 2517-2524
51. Belkaid Y., Piccirillo C.A., Mendez S., Shevach E.M., and Sacks D.L. CD4 + CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420 6915 (2002) 502-507
52. Suffia I.J., Reckling S.K., Piccirillo C.A., Goldszmid R.S., and Belkaid Y. Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med 203 3 (2006) 777-788
53. Stager S., Maroof A., Zubairi S., Sanos S.L., Kopf M., and Kaye P.M. Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10+ CD4+ T cells. Eur J Immunol 36 7 (2006) 1764-1771
54. Nylen S., and Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28 9 (2007) 378-384
55. Colino J., and Snapper C.M. Dendritic cells, new tools for vaccination. Microbes Infect 5 4 (2003) 311-319
56. Eggert A.A., Schreurs M.W., Boerman O.C., Oyen W.J., de Boer A.J., Punt C.J., et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59 14 (1999) 3340-3345
57. Berberich C., Ramirez-Pineda J.R., Hambrecht C., Alber G., Skeiky Y.A., and Moll H. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 170 6 (2003) 3171-3179
58. Fajardo-Moser M., Berzel S., and Moll H. Mechanisms of dendritic cell-based vaccination against infection. Int J Med Microbiol 298 1-2 (2008) 11-20
59. Ramirez-Pineda J.R., Frohlich A., Berberich C., and Moll H. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J Immunol 172 10 (2004) 6281-6289
60. Remer K.A., Apetrei C., Schwarz T., Linden C., and Moll H. Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice. Eur J Immunol 37 9 (2007) 2463-2473
61. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 408 6813 (2000) 740-745
62. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 199 (2004) 227-250
63. Grohmann U., Belladonna M.L., Bianchi R., Orabona C., Ayroldi E., Fioretti M.C., et al. IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity 9 3 (1998) 315-323
64. Watford W.T., Moriguchi M., Morinobu A., and O'Shea J.J. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14 5 (2003) 361-368
65. Zimmermann S., Dalpke A., and Heeg K. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections. Int J Med Microbiol 298 1-2 (2008) 39-44
66. Nicolette C.A., Healey D., Tcherepanova I., Whelton P., Monesmith T., Coombs L., et al. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine 25 Suppl. 2 (2007) B47-B60